

CAMZYOS® REMS

Healthcare Provider Knowledge Assessment

Instructions:

1. Complete and submit this **Healthcare Provider Knowledge Assessment** to the REMS:

- ▶ Online at **CAMZYOSREMS.com**, or
- ▶ Print and fax the form to the CAMZYOS REMS at 833-299-9539

2. To complete certification, enroll in the REMS by completing and submitting the **Healthcare Provider Enrollment Form**

Complete all required fields on this form to avoid a delay in the enrollment process. You will be notified by email of the status of your certification within 1 business day once the **Healthcare Provider Enrollment Form** has also been submitted.

Healthcare Provider Information (Fields marked * are REQUIRED)		
*First Name:	Middle Initial:	*Last Name:
*Healthcare Provider NPI #:		
*Phone: _____ <small>Area Code/Telephone Number</small>	*Fax: _____ <small>Area Code/Fax Number</small>	
*Email: _____		

For Questions 1–10, select the correct answer. All questions must be answered correctly.

Question 1

The risk being mitigated in the CAMZYOS REMS is:

- ☐ A. Liver function test elevations (>3 times the upper limit of normal)
- ☐ B. Neutropenia
- ☐ C. Heart failure due to systolic dysfunction
- ☐ D. Severe skin reactions

Question 2

Which of the following **is** an objective of the CAMZYOS REMS?

- ☐ A. Monitor for detection of heart failure due to systolic dysfunction with periodic echocardiograms
- ☐ B. Reduce liver toxicity caused by CAMZYOS
- ☐ C. Screen for drug interactions prior to each dispense
- ☐ D. Options A and B only
- ☐ E. Options A and C only
- ☐ F. None of the above

Question 3

What is the recommended starting dose of CAMZYOS?

- ☐ A. 2.5 mg once daily
- ☐ B. 5 mg once daily (or 2.5 mg for patients on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor)
- ☐ C. 10 mg every other day



For internal use only

Phone: 833-628-7367
Fax: 833-299-9539
CAMZYOSREMS.com

CAMZYOS® REMS

Healthcare Provider Knowledge Assessment

Question 4

Prior to and during treatment with CAMZYOS, each individual patient needs to receive counseling from their healthcare provider, using the **Patient Brochure**, on:

- ☐ A. The risk of drug-drug interactions with CYP2C19 or CYP3A4 inhibitors and inducers
- ☐ B. The risk of heart failure due to systolic dysfunction
- ☐ C. How to recognize and respond to the symptoms of heart failure due to systolic dysfunction
- ☐ D. The need to inform healthcare providers of all the prescription and nonprescription medications they take
- ☐ E. The need for echocardiograms during treatment with CAMZYOS
- ☐ F. All of the above

Question 5

Echocardiograms are required at each of the following time points while on CAMZYOS, **except**:

- ☐ A. Prior to initiation of treatment
- ☐ B. 4 weeks after initiation of treatment
- ☐ C. 8 weeks after initiation of treatment
- ☐ D. 12 weeks after initiation of treatment
- ☐ E. Once per year starting in the second year
- ☐ F. 4 weeks after a dose increase or decrease

Question 6

Patients can elect not to enroll in the REMS and still receive treatment with CAMZYOS.

- ☐ A. TRUE
- ☐ B. FALSE

Question 7

A prescription for CAMZYOS must be sent to a certified pharmacy to be dispensed. Pharmacies certified in the REMS can dispense CAMZYOS.

- ☐ A. TRUE
- ☐ B. FALSE

Question 8

If during treatment with CAMZYOS a patient has an LVEF <50%, the following step(s) should be followed:

- ☐ A. Treatment should be interrupted for 4 weeks
- ☐ B. Echocardiogram should be repeated after 4 weeks
- ☐ C. Once LVEF is ≥50%, treatment may be reinitiated at the next lower dose level
- ☐ D. All of the above

Question 9

In order for patients to continue treatment with CAMZYOS, the healthcare provider or designee is required to submit a **Patient Status Form** after each required echocardiogram.

- ☐ A. TRUE
- ☐ B. FALSE

Question 10

If a patient must begin to use a moderate to strong CYP3A4 or a weak to moderate CYP2C19 inhibitor during CAMZYOS therapy, what must occur?

- ☐ A. CAMZYOS must be discontinued
- ☐ B. The dose of CAMZYOS must be increased by one level
- ☐ C. The moderate to strong CYP3A4 or weak to moderate CYP2C19 inhibitor must be discontinued
- ☐ D. The dose of CAMZYOS must be decreased by one level



For internal use only